MAM
HRMY icon

Meeder Asset Management’s Harmony Biosciences HRMY Stock Holding History

Meeder Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-101
Closed -$4K – 1327
2022
Q3 		$4K Sell
101
-2
-2% -$98 ﹤0.01% 1641
2022
Q2 		$5K Sell
103
-3
-3% -$135 ﹤0.01% 1641
2022
Q1 		$5K Buy
106
+73
+221% +$2.98K ﹤0.01% 1794
2021
Q4 		$1K Buy
+33
New +$1.31K ﹤0.01% 1026

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Meeder Asset Management's HRMY Position: Q4 2022 in Review

Meeder Asset Management sold out of Harmony Biosciences (HRMY) in Q4 2022, closing a stake of 101 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in HRMY in Q4 2021 and held it in 4 quarters. The position peaked at $5K in Q2 2022. 242 funds tracked by Wall St. Rank hold HRMY as of Q4 2022.

  • Meeder Asset Management reported no remaining Harmony Biosciences position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 101 Harmony Biosciences shares in Q4 2022, an estimated $4K.
  • Meeder Asset Management first reported a position in Harmony Biosciences in Q4 2021 and held it in 4 quarters.
  • Meeder Asset Management's Harmony Biosciences position peaked at $5K in Q2 2022.
  • 242 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.